Filing Details

Accession Number:
0000930413-25-000708
Form Type:
13G Filing
Publication Date:
2025-02-25 19:00:00
Filed By:
Iroquois Capital Management, LLC
Company:
Petros Pharmaceuticals Inc.
Filing Date:
2025-02-26
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Iroquois Capital Management, LLC 0 902,084 3.6%
Richard Abbe 0 2,527,084 9.99%
Kimberly Page 0 902,084 3.6%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Includes 27,084 shares of Common Stock issuable upon the exercise of the Warrants (as defined in Item 4) and/or conversion of the Preferred Shares (as defined in Item 4) (See Item 4). As more fully described in Item 4, certain Warrants are subject to a 9.99% Beneficial Ownership Blocker and certain Warrants and Preferred Shares are subject to a 4.99% Beneficial Ownership Blocker, and the percentage set forth in row (11) gives effect to such Beneficial Ownership Blockers (as defined in Item 4). The shares reported in rows (6), (8) and (9) show the number of shares of Common Stock issuable upon conversion and/or exercise of such reported securities, giving effect to the Beneficial Ownership Blockers.


SCHEDULE 13G



Comment for Type of Reporting Person:  Includes 27,084 shares of Common Stock issuable upon the exercise of the Warrants (as defined in Item 4) and/or conversion of the Preferred Shares (as defined in Item 4) (See Item 4). As more fully described in Item 4, certain Warrants are subject to a 9.99% Beneficial Ownership Blocker and certain Warrants and Preferred Shares are subject to a 4.99% Beneficial Ownership Blocker, and the percentage set forth in row (11) gives effect to such Beneficial Ownership Blockers (as defined in Item 4). The shares reported in rows (6), (8) and (9) show the number of shares of Common Stock issuable upon conversion and/or exercise of such reported securities, giving effect to the Beneficial Ownership Blockers.


SCHEDULE 13G



Comment for Type of Reporting Person:  Includes 27,084 shares of Common Stock issuable upon the exercise of the Warrants (as defined in Item 4) and/or conversion of the Preferred Shares (as defined in Item 4) (See Item 4). As more fully described in Item 4, certain Warrants are subject to a 9.99% Beneficial Ownership Blocker and certain Warrants and Preferred Shares are subject to a 4.99% Beneficial Ownership Blocker, and the percentage set forth in row (11) gives effect to such Beneficial Ownership Blockers (as defined in Item 4). The shares reported in rows (6), (8) and (9) show the number of shares of Common Stock issuable upon conversion and/or exercise of such reported securities, giving effect to the Beneficial Ownership Blockers.


SCHEDULE 13G


 
Iroquois Capital Management, LLC
 
Signature:/s/ Richard Abbe
Name/Title:Richard Abbe, President
Date:02/25/2025
 
Richard Abbe
 
Signature:/s/ Richard Abbe
Name/Title:Richard Abbe
Date:02/25/2025
 
Kimberly Page
 
Signature:/s/ Kimberly Page
Name/Title:Kimberly Page
Date:02/25/2025
Exhibit Information

Exhibit 1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.